ResearchSafe

PE 22-28 TREK-1 blocker, anyone following the preclinical antidepressant angle?

Posted by sleep_coastal in Research & News - 6 points, 5 comments.

Been reading up on PE 22-28, the spadin-derived peptide that blocks the TREK-1 potassium channel. The animal data on rapid antidepressant effects and neurogenesis is interesting. You can read the profile here: /peptides/pe-22-28.

What catches my attention is the mechanism. Instead of messing with serotonin reuptake directly, it blocks a background potassium channel, which enhances serotonergic signaling downstream. That is a different lever than SSRIs pull.

Anecdotally, the cognitive peptides I have tried, Semax and Adamax, felt like they did something within days rather than weeks. If PE 22-28 actually works in humans the way it does in animal models, that fast onset would line up with what I have noticed from other neuroplasticity-oriented compounds. But this is ALL preclinical.

No human safety data. No established dosing. The short half-life as a peptide is a real problem too.

You would probably need some kind of modified delivery to get meaningful exposure. I keep seeing people in biohacking circles talk about it like it is right around the corner. It is not.

The jump from mouse synaptogenesis to human mood improvement is huge and often does not survive the trip. Still, the TREK-1 target itself feels promising. Anyone else been following the TREK-1 research trail, or tried anything in this spadin family?

Comments

  • greg_codes: The trek-1 mechanism is genuinely interesting ngl, different pathway than the usual serotonin stuff. But yeah the half-life issue is brutal. Spadin itself had the same problem and that is why it never went anywhere clinically? Pe 22-28 is supposedly more stable but "more stable than spadin" is a pretty low bar. I ran semax for a few weeks and felt something within days too, could just be placebo though. Hard to separate subjective mood from confirmation bias when you are expecting a fast onset.
  • curious_scientist: Yeah the half‑life is rough even if it’s a bit better than spadin. I tried PE 22‑28 once at 100 µg subq and felt a slight mood lift after two days, but it faded fast and I couldn’t tell if it was real. Did you notice any sleep or HRV changes?
  • tiredmegan: "More stable than spadin" is a bar so low you could trip over it, fair play for calling that out. The placebo thing is dead on though, every time I have tried something expecting a fast onset I swear I feel it in two days. Could just be me being desperate for it to work. Has anyone actually seen any real half-life data for PE 22-28 or is it all just "trust me bro it lasts longer"?
  • sleep_coastal: The half-life question is a good one and I don't have a solid answer. What I've seen floating around is mostly derived from the modified spadin analogs, not PE 22-28 specifically. The structural tweaks are supposed to resist degradation but I haven't found actual pharmacokinetic data, just inference from related compounds. That "trust me bro" gap is exactly why I haven't pulled the trigger on it yet. And yeah, the expectation placebo is REAL, I caught myself doing it with Adamax big time.
  • sleep_coastal: Haven't actually pulled the trigger on PE 22-28 myself yet, so no sleep or HRV data to share. Your 100 µg subq experience is about what I'd expect given that half-life issue. Two days of slight lift then fade sounds like it's clearing before it can do much. Anecdotally, the mood lift could just be novelty too. Did you try splitting doses or just the single shot?
  • sleep_coastal: Yeah the spadin comparison is exactly what makes me cautious. "More stable than spadin" is basically saying it lasts slightly longer than something that barely lasted at all. Not exactly reassuring. Anecdotally the Semax fast-onset thing, I totally agree confirmation bias is a real problem there. For me it felt like sharper focus within two or three days but I have no way to rule out expectation effects. That is honestly why I keep coming back to wanting human data before getting too excited ab

Community discussion - research and educational context only. Not medical advice.